Radiotherapy and temozolomide in anaplastic astrocytoma: A retrospective multicenter study by the Central Nervous System Study Group of AIRO (Italian Association of Radiation Oncology)

Silvia Scoccianti, Stefano Maria Magrini, Umberto Ricardi, Beatrice Detti, Marco Krengli, Salvatore Parisi, Filippo Bertoni, Guido Sotti, Samantha Cipressi, Vincenzo Tombolini, Stefano Dall'Oglio, Marco Lioce, Calogero Saieva, Michela Buglione, Cristina Mantovani, Giovanni Rubino, Paolo Muto, Vincenzo Fusco, Laura Fariselli, Costantino De RenzisLaura Masini, Riccardo Santoni, Luigi Pirtoli, Giampaolo Biti

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Although the evidence for the benefit of adding temozolomide (TMZ) to radiotherapy (RT) is limited to glioblastoma patients, there is currently a trend toward treating anaplastic astrocytomas (AAs) with combined RT TMZ. The aim of the present study was to describe the patterns of care of patients affected by AA and, particularly, to compare the outcome of patients treated exclusively with RT with those treated with RT TMZ. Data of 295 newly diagnosed AAs treated with postoperative RT TMZ in the period from 2002 to 2007 were reviewed. More than 75 of patients underwent a surgical removal. All the patients had postoperative RT; 86.1 of them were treated with 3D-conformal RT (3D-CRT). Sixty-seven percent of the entire group received postoperative chemotherapy with TMZ (n 198). One-hundred sixty-six patients received both concomitant and sequential TMZ. Prescription of postoperative TMZ increased in the most recent period (20052007). One-and 4-year survival rates were 70.2 and 28.6, respectively. No statistically significant improvement in survival was observed with the addition of TMZ to RT (P .59). Multivariate analysis showed the statistical significance of age, presence of seizures, Recursive Partitioning Analysis classes IIII, extent of surgical removal, and 3D-CRT. Changes in the care of AA over the past years are documented. Currently there is not evidence to justify the addition of TMZ to postoperative RT for patients with newly diagnosed AA outside a clinical trial. Results of prospective and randomized trials are needed.

Original languageEnglish
Pages (from-to)798-807
Number of pages10
JournalNeuro-Oncology
Volume14
Issue number6
DOIs
Publication statusPublished - Jun 2012

Fingerprint

temozolomide
Radiation Oncology
Astrocytoma
Multicenter Studies
Radiotherapy
Central Nervous System
Retrospective Studies
Conformal Radiotherapy
Glioblastoma

Keywords

  • anaplastic astrocytoma
  • chemotherapy
  • radiotherapy
  • temozolomide
  • WHO grade III gliomas

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Clinical Neurology

Cite this

Radiotherapy and temozolomide in anaplastic astrocytoma : A retrospective multicenter study by the Central Nervous System Study Group of AIRO (Italian Association of Radiation Oncology). / Scoccianti, Silvia; Magrini, Stefano Maria; Ricardi, Umberto; Detti, Beatrice; Krengli, Marco; Parisi, Salvatore; Bertoni, Filippo; Sotti, Guido; Cipressi, Samantha; Tombolini, Vincenzo; Dall'Oglio, Stefano; Lioce, Marco; Saieva, Calogero; Buglione, Michela; Mantovani, Cristina; Rubino, Giovanni; Muto, Paolo; Fusco, Vincenzo; Fariselli, Laura; De Renzis, Costantino; Masini, Laura; Santoni, Riccardo; Pirtoli, Luigi; Biti, Giampaolo.

In: Neuro-Oncology, Vol. 14, No. 6, 06.2012, p. 798-807.

Research output: Contribution to journalArticle

Scoccianti, S, Magrini, SM, Ricardi, U, Detti, B, Krengli, M, Parisi, S, Bertoni, F, Sotti, G, Cipressi, S, Tombolini, V, Dall'Oglio, S, Lioce, M, Saieva, C, Buglione, M, Mantovani, C, Rubino, G, Muto, P, Fusco, V, Fariselli, L, De Renzis, C, Masini, L, Santoni, R, Pirtoli, L & Biti, G 2012, 'Radiotherapy and temozolomide in anaplastic astrocytoma: A retrospective multicenter study by the Central Nervous System Study Group of AIRO (Italian Association of Radiation Oncology)', Neuro-Oncology, vol. 14, no. 6, pp. 798-807. https://doi.org/10.1093/neuonc/nos081
Scoccianti, Silvia ; Magrini, Stefano Maria ; Ricardi, Umberto ; Detti, Beatrice ; Krengli, Marco ; Parisi, Salvatore ; Bertoni, Filippo ; Sotti, Guido ; Cipressi, Samantha ; Tombolini, Vincenzo ; Dall'Oglio, Stefano ; Lioce, Marco ; Saieva, Calogero ; Buglione, Michela ; Mantovani, Cristina ; Rubino, Giovanni ; Muto, Paolo ; Fusco, Vincenzo ; Fariselli, Laura ; De Renzis, Costantino ; Masini, Laura ; Santoni, Riccardo ; Pirtoli, Luigi ; Biti, Giampaolo. / Radiotherapy and temozolomide in anaplastic astrocytoma : A retrospective multicenter study by the Central Nervous System Study Group of AIRO (Italian Association of Radiation Oncology). In: Neuro-Oncology. 2012 ; Vol. 14, No. 6. pp. 798-807.
@article{de27592bd5d843388ffeb030338b7edc,
title = "Radiotherapy and temozolomide in anaplastic astrocytoma: A retrospective multicenter study by the Central Nervous System Study Group of AIRO (Italian Association of Radiation Oncology)",
abstract = "Although the evidence for the benefit of adding temozolomide (TMZ) to radiotherapy (RT) is limited to glioblastoma patients, there is currently a trend toward treating anaplastic astrocytomas (AAs) with combined RT TMZ. The aim of the present study was to describe the patterns of care of patients affected by AA and, particularly, to compare the outcome of patients treated exclusively with RT with those treated with RT TMZ. Data of 295 newly diagnosed AAs treated with postoperative RT TMZ in the period from 2002 to 2007 were reviewed. More than 75 of patients underwent a surgical removal. All the patients had postoperative RT; 86.1 of them were treated with 3D-conformal RT (3D-CRT). Sixty-seven percent of the entire group received postoperative chemotherapy with TMZ (n 198). One-hundred sixty-six patients received both concomitant and sequential TMZ. Prescription of postoperative TMZ increased in the most recent period (20052007). One-and 4-year survival rates were 70.2 and 28.6, respectively. No statistically significant improvement in survival was observed with the addition of TMZ to RT (P .59). Multivariate analysis showed the statistical significance of age, presence of seizures, Recursive Partitioning Analysis classes IIII, extent of surgical removal, and 3D-CRT. Changes in the care of AA over the past years are documented. Currently there is not evidence to justify the addition of TMZ to postoperative RT for patients with newly diagnosed AA outside a clinical trial. Results of prospective and randomized trials are needed.",
keywords = "anaplastic astrocytoma, chemotherapy, radiotherapy, temozolomide, WHO grade III gliomas",
author = "Silvia Scoccianti and Magrini, {Stefano Maria} and Umberto Ricardi and Beatrice Detti and Marco Krengli and Salvatore Parisi and Filippo Bertoni and Guido Sotti and Samantha Cipressi and Vincenzo Tombolini and Stefano Dall'Oglio and Marco Lioce and Calogero Saieva and Michela Buglione and Cristina Mantovani and Giovanni Rubino and Paolo Muto and Vincenzo Fusco and Laura Fariselli and {De Renzis}, Costantino and Laura Masini and Riccardo Santoni and Luigi Pirtoli and Giampaolo Biti",
year = "2012",
month = "6",
doi = "10.1093/neuonc/nos081",
language = "English",
volume = "14",
pages = "798--807",
journal = "Neuro-Oncology",
issn = "1522-8517",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Radiotherapy and temozolomide in anaplastic astrocytoma

T2 - A retrospective multicenter study by the Central Nervous System Study Group of AIRO (Italian Association of Radiation Oncology)

AU - Scoccianti, Silvia

AU - Magrini, Stefano Maria

AU - Ricardi, Umberto

AU - Detti, Beatrice

AU - Krengli, Marco

AU - Parisi, Salvatore

AU - Bertoni, Filippo

AU - Sotti, Guido

AU - Cipressi, Samantha

AU - Tombolini, Vincenzo

AU - Dall'Oglio, Stefano

AU - Lioce, Marco

AU - Saieva, Calogero

AU - Buglione, Michela

AU - Mantovani, Cristina

AU - Rubino, Giovanni

AU - Muto, Paolo

AU - Fusco, Vincenzo

AU - Fariselli, Laura

AU - De Renzis, Costantino

AU - Masini, Laura

AU - Santoni, Riccardo

AU - Pirtoli, Luigi

AU - Biti, Giampaolo

PY - 2012/6

Y1 - 2012/6

N2 - Although the evidence for the benefit of adding temozolomide (TMZ) to radiotherapy (RT) is limited to glioblastoma patients, there is currently a trend toward treating anaplastic astrocytomas (AAs) with combined RT TMZ. The aim of the present study was to describe the patterns of care of patients affected by AA and, particularly, to compare the outcome of patients treated exclusively with RT with those treated with RT TMZ. Data of 295 newly diagnosed AAs treated with postoperative RT TMZ in the period from 2002 to 2007 were reviewed. More than 75 of patients underwent a surgical removal. All the patients had postoperative RT; 86.1 of them were treated with 3D-conformal RT (3D-CRT). Sixty-seven percent of the entire group received postoperative chemotherapy with TMZ (n 198). One-hundred sixty-six patients received both concomitant and sequential TMZ. Prescription of postoperative TMZ increased in the most recent period (20052007). One-and 4-year survival rates were 70.2 and 28.6, respectively. No statistically significant improvement in survival was observed with the addition of TMZ to RT (P .59). Multivariate analysis showed the statistical significance of age, presence of seizures, Recursive Partitioning Analysis classes IIII, extent of surgical removal, and 3D-CRT. Changes in the care of AA over the past years are documented. Currently there is not evidence to justify the addition of TMZ to postoperative RT for patients with newly diagnosed AA outside a clinical trial. Results of prospective and randomized trials are needed.

AB - Although the evidence for the benefit of adding temozolomide (TMZ) to radiotherapy (RT) is limited to glioblastoma patients, there is currently a trend toward treating anaplastic astrocytomas (AAs) with combined RT TMZ. The aim of the present study was to describe the patterns of care of patients affected by AA and, particularly, to compare the outcome of patients treated exclusively with RT with those treated with RT TMZ. Data of 295 newly diagnosed AAs treated with postoperative RT TMZ in the period from 2002 to 2007 were reviewed. More than 75 of patients underwent a surgical removal. All the patients had postoperative RT; 86.1 of them were treated with 3D-conformal RT (3D-CRT). Sixty-seven percent of the entire group received postoperative chemotherapy with TMZ (n 198). One-hundred sixty-six patients received both concomitant and sequential TMZ. Prescription of postoperative TMZ increased in the most recent period (20052007). One-and 4-year survival rates were 70.2 and 28.6, respectively. No statistically significant improvement in survival was observed with the addition of TMZ to RT (P .59). Multivariate analysis showed the statistical significance of age, presence of seizures, Recursive Partitioning Analysis classes IIII, extent of surgical removal, and 3D-CRT. Changes in the care of AA over the past years are documented. Currently there is not evidence to justify the addition of TMZ to postoperative RT for patients with newly diagnosed AA outside a clinical trial. Results of prospective and randomized trials are needed.

KW - anaplastic astrocytoma

KW - chemotherapy

KW - radiotherapy

KW - temozolomide

KW - WHO grade III gliomas

UR - http://www.scopus.com/inward/record.url?scp=84862182813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862182813&partnerID=8YFLogxK

U2 - 10.1093/neuonc/nos081

DO - 10.1093/neuonc/nos081

M3 - Article

C2 - 22539339

AN - SCOPUS:84862182813

VL - 14

SP - 798

EP - 807

JO - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

IS - 6

ER -